Project Grant R44TR006374
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Watertown, MA 02472, USA
Similar Awards
- The National Center for Advancing Translational Sciences at the National Institutes of Health, under the Department of Health and Human Services, awarded $957,707 to Cytoterra Inc. on July 1, 2026, through the NCATS Program (CFDA 93.350). Cytoterra will develop and validate a high-throughput genomic integrity assessment platform for allogeneic cell therapies. The project combines genomic proximity mapping technology with whole exome sequencing in a platform called Cytoterra Plus to detect...
- The National Center for Advancing Translational Sciences awarded Goeppert LLC, a Philadelphia-based small disadvantaged business, $350,000 on July 1, 2026, under CFDA 93.350 (National Center for Advancing Translational Sciences) to develop NANO-PAVE, a nanopore-based platform for assessing adeno-associated virus (AAV) capsid quality in gene therapy manufacturing. NANO-PAVE addresses a critical bottleneck in AAV clinical translation: current quality-control assays (ELISA, ddPCR, analytical...
- The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, awarded The Broad Institute, Inc. $436,250 on May 1, 2026, under the NCATS program (CFDA 93.350) to develop and validate the RAPID (Rare Disease Analysis Through Pooled Image-Based Identification of Drugs) platform for drug repurposing in rare disorders. The Broad Institute will develop a massively parallel screening platform that integrates pooled optical variant identification,...
- The federal Project Grant award of $350,000 was provided by the National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, to Vivosphere LLC in Auburn, AL. The funding will support the development of "Vivospheres", which are tissue-engineered spheroidal models for high-throughput screening. The project aims to establish Vivospheres as a more consistent and flexible 3D cell culture system compared to traditional self-aggregation methods, enabling...
- The National Institutes of Health National Center for Advancing Translational Sciences awarded $306,872 to Endless Vectors Bioscience on September 3, 2026, under the NCATS Program (CFDA 93.350) to develop and validate a cell cycle-dependent replicating adeno-associated virus platform for treating neonatal inborn errors of metabolism. Endless Vectors will assess tissue-specific replication, episomal persistence, and long-term safety and efficacy of the CCRAAV platform in neonatal mouse liver...
- The National Center for Advancing Translational Sciences awarded Sollus Therapeutics, Inc. $322,576 on July 1, 2026, under the NCATS program (CFDA 93.350) to develop a modular, high-throughput screening platform for optimizing chimeric antigen receptor (CAR) designs. The project addresses limitations in CAR T cell therapy by creating a platform to systematically screen and optimize CAR architectures across antigens, diseases, and modalities. Work focuses on three aims: screening large...
- The National Center for Advancing Translational Sciences awarded Intero Biosystems Inc. $1.046897 million in project grant funding on July 1, 2026, under CFDA 93.350. Intero Biosystems will develop a stem cell-derived human intestinal organoid platform for drug discovery and preclinical testing. The platform incorporates multiple cell types of the native intestine to model both normal intestinal function and disease processes. Phase II work will scale production methods and validate assay...
- Grant Award Summary Spectral Therapeutics, Inc. received a $322,388 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective August 1, 2025, through July 31, 2026, to develop and validate an optical-encoded bead technology platform for large-scale molecular library generation. The project addresses a critical bottleneck in combinatorial drug discovery by creating stimulated emission-encoded beads that enable instantaneous decoding during...
- Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...
- The National Center for Advancing Translational Sciences awarded Aigene Inc. $349,890 on July 1, 2026, under the NCATS program (CFDA 93.350) to develop a novel home and laboratory system for improved cell-free DNA screening and monitoring using transrenal DNA. The project addresses limitations in blood cell-free DNA analysis for diagnostic and monitoring applications including perinatal screening, transplant monitoring, cancer therapy selection, and multiple-cancer early detection. The system...